Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies

A Correction to this article was published on 21 July 2020

This article has been updated

This is a preview of subscription content, access via your institution.

Change history

  • 21 July 2020

    The Table 2 in the original version of the above article was incorrectly presented. The data where misaligned during publication process.]

References

  1. 1.

    Westra J, Rondaan C, van Assen S, Bijl M (2015) Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 11:135–145

    CAS  Article  Google Scholar 

  2. 2.

    Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, Pineda C, Vizzotti C (2018) Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol 24:138–147

    Article  Google Scholar 

  3. 3.

    Weycker D, Farkouh RA, Strutton DR et al (2016) Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res 16:182

    Article  Google Scholar 

  4. 4.

    World Health Organization (2008) Position paper on 23-valent pneumococcal polysaccharide vaccine. Wkly Epidemiol Rec 83:373–384

    Google Scholar 

  5. 5.

    Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2014) Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 32:2364–2374. https://doi.org/10.1016/j.vaccine.2014.02.002

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Jackson LA, Gurtman A, van Cleeff M et al (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594–3602. https://doi.org/10.1016/j.vaccine.2013.04.084

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Lesprit P, Pédrono G, Molina JM et al (2007) Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 21:2425–2434. https://doi.org/10.1097/QAD.0b013e3282887e91

    Article  PubMed  Google Scholar 

  8. 8.

    Centers for Disease Control and Prevention (CDC) (2012) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 61:816–819

    Google Scholar 

  9. 9.

    Vieira de Rezende RP, Mattos GA, de Mello Leal Augusto R, Machado Gayer CR, Mendes Klumb E (2019) Predictors for seasonal influenza vaccination and reasons for inadequate vaccination coverage against a broad spectrum of vaccine-preventable diseases: a cross-sectional study among a Brazilian cohort of adult patients with systemic lupus erythematosus. Lupus 28:794–796. https://doi.org/10.1177/0961203319846383

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Centers for Disease Control and Prevention (CDC) (2008) Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000-2008. MMWR Morb Mortal Wkly Rep 57:1148–1151

    Google Scholar 

  11. 11.

    Ministério da Saúde (2019) Manual dos Centros de Referência para Imunobiológicos especiais (5ª edição). Ministério da Saúde https://sbim.org.br/images/calendarios/manual-centros-referencia_imunobiologicos-especiais-5ed-web.pdf Accessed on Dec 15, 2019

  12. 12.

    World Health Organization (1993) International classification of diseases and related health problems, tenth revision: volume 2, instruction manual. World Health Organization, Geneva

    Google Scholar 

  13. 13.

    Sartori Vieira C, de Rezende RPV, Mendes Klumb E, Cardoso Mocarzel LO, Altenburg Gismondi R (2019) Mortality profile related to the spectrum of systemic connective tissue diseases: a retrospective, population-based, case-control study. Lupus 28:1498–1500

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Rodrigo Poubel Vieira de Rezende.

Ethics declarations

Disclosure

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

de Rezende, R.P.V., Klumb, E.M. & Pileggi, G.S. Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies. Clin Rheumatol 39, 1703–1705 (2020). https://doi.org/10.1007/s10067-020-05039-x

Download citation